Please use this identifier to cite or link to this item: http://hdl.handle.net/20.500.12188/12354
DC FieldValueLanguage
dc.contributor.authorBugiardini, Raffaeleen_US
dc.contributor.authorPavasović, Sašaen_US
dc.contributor.authorYoon, Jinsungen_US
dc.contributor.authorvan der Schaar, Mihaelaen_US
dc.contributor.authorSasko Kedeven_US
dc.contributor.authorMarija Vavlukisen_US
dc.contributor.authorVasiljevic, Zoranaen_US
dc.contributor.authorBergami, Mariaen_US
dc.contributor.authorMiličić, Davoren_US
dc.contributor.authorManfrini, Oliviaen_US
dc.contributor.authorCenko, Edinaen_US
dc.contributor.authorBadimon, Linaen_US
dc.date.accessioned2021-05-07T12:19:13Z-
dc.date.available2021-05-07T12:19:13Z-
dc.date.issued2020-09-20-
dc.identifier.urihttp://hdl.handle.net/20.500.12188/12354-
dc.description.abstractControversy exists as to whether low-dose aspirin use may give benefit in primary prevention of cardiovascular (CV) events. We hypothesized that the benefits of aspirin are underevaluated.en_US
dc.description.sponsorshipnoneen_US
dc.language.isoenen_US
dc.publisherELSEVERen_US
dc.relation.ispartofEClinicalMedicineen_US
dc.subjectAspirinen_US
dc.subjectPrimary preventionen_US
dc.subjectST segment elevation myocardial infarctionen_US
dc.titleAspirin for primary prevention of ST segment elevation myocardial infarction in persons with diabetes and multiple risk factorsen_US
dc.typeArticleen_US
dc.identifier.doi10.1016/j.eclinm.2020.100548-
dc.identifier.volume27-
item.grantfulltextopen-
item.fulltextWith Fulltext-
crisitem.author.deptFaculty of Medicine-
Appears in Collections:Faculty of Medicine: Journal Articles
Files in This Item:
File Description SizeFormat 
Aspirin for primary prevention of ST segment elevation myocardial.pdf1.47 MBAdobe PDFView/Open
Show simple item record

Page view(s)

123
checked on Oct 10, 2024

Download(s)

23
checked on Oct 10, 2024

Google ScholarTM

Check

Altmetric


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.